FDA vs. EMA: Key Differences in US & EU Drug Regulation

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the premier regulatory authorities for pharmaceuticals in the United States and European Union respectively. Although both agencies share the overarching goal of ensuring that medicines are safe, effective, and of high quality, they differ markedly in legal structure, scope of authority, review processes, and regulatory culture. The FDA is a centralized U.S. federal agency (under the Department of Health and Human Services) with direct authority to approve or reject products for the entire U.S. market, whereas the EMA is an EU-wide coordinating agency whose opinions are advisory – final marketing decisions in the EU are taken by the European Commission (EC). The FDA’s jurisdiction spans a wide range of products (prescription drugs, over-the-counter drugs, biologics, medical devices, vaccines, blood products, tobacco, even food additives), whereas the EMA focuses primarily on human (and veterinary) medicines, with limited input on devices. Organizationally, the FDA operates as a single agency with full-time in-house reviewers, while the EMA leverages a network of national regulatory experts (the CHMP and related committees) from EU member states (^[1]) (^[2]).

Key differences include:

• Approval Pathways and Processes: In the U.S., new drugs enter via an Investigational New Drug (IND) application and go through a New Drug Application (NDA) or Biologics License Application (BLA) process, with all final approvals coming from the FDA. In Europe, there are multiple routes: Centralized Procedure (single EMA/EC authorization for all EU states), Decentralized/Mutual Recognition (getting approval in one EU country then extending to others), and National Procedures. Companies must submit a Marketing Authorization Application (MAA) to the EMA (for centralized) or to national agencies. Unlike the FDA, which approves directly, the EMA issues a scientific opinion via its CHMP, after which the EC enacts a binding decision – a formality that almost always follows the EMA’s recommendation (^[3]) (^[4]).

• Review Timelines and Speed: Historically and on average the FDA has granted approvals more quickly. For example, a study of drugs approved 2011–2015 found the FDA’s median review was 306 days versus 383 days at the EMA (^[5]). A comprehensive 2013–2023 analysis confirmed the FDA uses “faster and more flexible approval pathways” and generally authorizes drugs earlier, often relying on surrogate endpoints and limited data especially under accelerated programs, whereas the EMA “focuses on long-term safety” (^[6]). The 2024 and 2025 figures should not be treated as directly comparable measures of total agency output. In 2025, FDA's CDER reported 46 novel-drug approvals, while EMA reported 38 recommended medicines containing a new active substance; the agencies use different scopes and reporting definitions. Likewise, in the COVID-19 pandemic, the FDA’s Emergency Use Authorizations averaged about 36 days from submission, compared to 24 days for the EMA’s Conditional Marketing Authorizations – small differences driven partly by submission timing but reflecting each agency’s regulatory tools (^[7]).

• Expedited and Special Programs: Both agencies have special programs for serious diseases and unmet needs, but the structure differs. The FDA has multiple overlapping designations (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) that can be used concurrently, whereas the EMA offers a single Accelerated Assessment pathway (faster review for major innovations) plus Conditional Approval for compelling but incomplete data. The EMA also has the PRIME scheme (priority medicines) to support early development of critical drugs. Notably, the FDA Omnibus Reform Act (FDORA, December 2022) strengthened FDA's Accelerated Approval program by granting the agency expedited withdrawal authority and requiring mandatory timelines for confirmatory studies — changes that took full effect in 2024–2025. These differences mean U.S. companies often pursue parallel FDA and EMA advice to align on trial designs, or newer “parallel scientific advice” mechanisms where both agencies advise at once (^[8]) (^[9]).

• Evidence and Standards: By statute, FDA typically requires “substantial evidence” of efficacy (traditionally interpreted as ≥2 well-controlled trials, or sometimes 1 trial with confirmatory data) (^[10]), while the EMA also requires robust data but often emphasizes the consistency and generalizability of results to European populations. Both use risk–benefit frameworks, but the FDA has been more willing to accept surrogates and fewer trials under accelerated pathways (^[6]). The EMA routinely mandates Pediatric Investigation Plans (PIPs) for marketing authorizations, whereas the FDA requires Pediatric Study Plans (PSPs) – similar in intent but differing in submission timing and enforcement. Orphan drug incentives exist on both sides, but details differ (e.g. 7-year market exclusivity in the U.S. vs 10 years in the EU, differing tax credits and fee waivers).

• Manufacturing Quality (GMP): Both enforce Good Manufacturing Practices, but U.S. cGMP (21 CFR Part 210/211) tends to be more prescriptive and detailed, whereas EU GMP (EudraLex Volume 4) is more principle-based emphasizing quality systems and risk management (^[11]) (^[12]). FDA inspectors are federal employees and can issue FDA-specific enforcement actions (warning letters, import alerts) swiftly, while the EMA relies on coordinated inspections by national agencies. Documentation differences exist as well; for example, the FDA typically requires retaining batch records for at least 1 year post-expiry, whereas EU GMP requires batch documentation to be kept for at least one year after the batch expiry date or at least five years after certification by the Qualified Person, whichever is longer (^[13]) (^[14]).

• Post-Marketing Surveillance: Both agencies conduct pharmacovigilance. The FDA collects adverse event reports through MedWatch, requires Risk Evaluation and Mitigation Strategies (REMS) for certain drugs, and can mandate label changes or withdraw approvals. The EMA monitors safety via EudraVigilance, Periodic Safety Update Reports, and the EU’s Pharmacovigilance Risk Assessment Committee (PRAC) may impose risk mitigation (e.g. educational programs) or even suspend marketing. In practice, both agencies act when serious safety concerns emerge, but EMA processes involve EU member states in a decentralized way.

• Labeling and Advertising: The FDA regulates direct-to-consumer (DTC) advertising of prescription drugs on TV and radio; it does not generally pre-approve every advertisement before dissemination. Prescription-drug DTC advertising is prohibited in the EU, while some over-the-counter medicine advertising may be permitted under applicable EU and national rules. Package inserts also differ: FDA labels list U.S. contact info and U.S.-centric instructions, while EU Summary of Product Characteristics (SmPC) must be submitted in all official EU languages and follow EU-specific formats.

• Organizational/Financial Structure: The FDA is funded partially by Congressional appropriations but heavily influenced by user fees (PDUFA, BLA fees), which require agency performance goals and timelines (currently about 70% of the drug budget comes from industry fees (^[15])). The EMA is funded primarily by fees and charges, alongside an EU contribution for public-health issues and other sources; it compensates national medicines regulatory authorities from its budget for work they perform in the EU medicines regulatory network. EMA fees are not linked to shorter review times (^[16]). This structural difference means the FDA is under more time pressure – which some analysts argue creates industry influence and a focus on speed – whereas the EMA’s stable deadlines allow more emphasis on thoroughness (^[15]) (^[16]).

Collectively, these differences have real-world impacts: companies often must run dual strategies, designing trials to meet both sets of requirements and sometimes even conducting extra studies to satisfy one regulator. However, broad outcomes often converge – about 75–80% of major drugs end up approved in both regions (^[17]) (^[6]). Recent trends (harmonization efforts like ICH guidelines, FDA–EMA work-sharing clusters, and joint scientific advice mechanisms) aim to narrow the gaps. In January 2026, the FDA and EMA jointly published 10 guiding principles for the use of AI and machine learning in drug development, signaling deepening collaboration on emerging technologies. Meanwhile, the EU pharmaceutical package reached a provisional political agreement in December 2025. As of the latest European Parliament legislative tracker, formal Council adoption remained expected after legal and linguistic checks, and Parliament's final plenary vote had not yet been scheduled (with an indicative autumn 2026 date). In the United States, Dr. Marty Makary served as FDA Commissioner from April 2025 through May 2026; FDA currently lists Kyle A. Diamantas, J.D., as Acting Commissioner of Food and Drugs. The effect of leadership changes, budgets, and staffing on review capacity should not be assumed without current evidence. FDA leadership profile FDA commissioner history Nonetheless, differences in legal frameworks and procedures remain relevant to drug developers, patients, and health systems on both sides of the Atlantic.

The pharmaceutical regulatory framework in the U.S. and Europe has evolved over many decades to protect public health while enabling the introduction of beneficial new therapies. The FDA traces its roots to the 1906 Pure Food and Drugs Act and the 1938 Federal Food, Drug, and Cosmetic (FD&C) Act, gaining broad authority over drug safety, efficacy, and manufacturing. It became the singular U.S. regulator with the mandate to review and license drugs for all 50 states (^[18]). By contrast, European drug regulation emerged from a decentralized set of national systems. Early EU efforts to harmonize drug laws began with Directive 65/65/EEC (1965), which required each member state to use standardized dossiers for approving medicines (^[19]). The modern European Medicines Agency (EMA) itself was established only in 1995 (with industry and EU funding) to coordinate reviews and reduce duplication from before (^[2]). Its formation “harmonized processes in member-state agencies… to reduce costs to drug companies” that had to obtain separate national licenses (^[2]). Even so, the EMA supplements rather than replaces national agencies: the EU now has four distinct approval routes – centralized (EMA/EC), decentralized, mutual recognition, and purely national pathways (^[20]) (^[21]).

By design, the FDA is a U.S. federal agency within the Department of Health and Human Services whose decisions (NDA/BLA approvals or rejections) are final and nationwide (^[1]). The EMA is legally an EU-commissioned body: it evaluates marketing applications through expert committees (CHMP for human medicines) but cannot itself grant approvals (^[3]) (^[4]). Instead, the EC issues binding authorizations based on EMA opinions, a formality that has never been overturned in practice (^[3]). (By contrast, FDA approvals do not require any extra executive sign-off – the Director’s signature is final.)

These institutional structures create ongoing procedural distinctions. The FDA is a centralized U.S. federal regulator, while the EMA works through an EU medicines regulatory network that includes Member States and EEA countries. Over time both agencies have worked toward alignment—instituting the International Council on Harmonisation (ICH) guidelines globally and holding joint meetings—but key divergences persist due to their distinct legal mandates and cultures (^[22]) (^[10]). For example, the FDA was born as a consumer-protection regulator and emphasizes efficiency under statutory timelines (PDUFA) (^[23]) (^[15]), while EU law embeds a precautionary approach in areas like food and chemicals (not governed by EMA) and tends to emphasize post-marketing vigilance and public health impact. This report will systematically explore how these contrasting structures and histories translate into differences in regulatory frameworks, standards, and outcomes in the U.S. and Europe.

Agency Structure and Authority

FDA: The FDA is a single federal agency under HHS, organized into centers by product type (CDER for drugs, CBER for biologics, CDRH for devices, etc.) (^[1]). It has direct statutory authority from Congress to issue guidance, write regulations, and approve or reject marketing applications for its jurisdiction. The Center for Drug Evaluation and Research (CDER) employs full-time reviewers and pharmacologists, enabling in-house scientific evaluation and decision-making. Upon completion of an approved review, the FDA’s decision authorizes marketing of a drug throughout the U.S. simultaneously (^[24]) (^[6]). The FDA convenes expert advisory committees publicly for advice on difficult cases (e.g. drugs with safety controversies) but these are generally non-binding.

EMA: The EMA, by contrast, is an EU agency (not a ministry) with headquarters in Amsterdam (relocated from London after Brexit in 2019). It coordinates reviews via the EU medicines network: each Member State has a “competent authority” which contributes experts. The EMA’s CHMP is composed of scientific members nominated by the Member States (^[25]). For a centralized MAA, the CHMP designates rapporteurs (and co-rapporteurs) from national agencies to lead the dossier evaluation, bringing multi-country expertise. After the CHMP forms an opinion (usually by consensus vote (^[26])), that opinion is sent to the European Commission, which issues a legal marketing authorization. Day-to-day, EMA staff process submissions and facilitate these expert panels, but the final legal power lies with the Commission.

Thus, decision-making differs fundamentally. The FDA’s cascade is short: once its reviewers and leadership agree, the agency can immediately approve nationwide. The EMA’s process has an extra layer: even after a positive CHMP opinion, the EC typically takes 1-2 months to render a final authorization (though it almost always endorses CHMP). This decoupling means European approvals effectively involve two steps (CHMP opinion + EC authorization) (^[27]). On the other hand, involving multiple countries brings the benefit of diverse scientific perspectives and pooling of EU resources. A pharmaceutical company may see CHMP as bringing broader EU-wide input, whereas FDA review is a single-agency viewpoint. Moreover, because EMA staff sit separately from Member States’ agencies, EMA itself does not inspect manufacturing sites—the responsibility lies with national inspectors (often delegated by EMA). In contrast, FDA inspectors are employed by the FDA and can conduct surprise inspections nationwide, issuing Federal Form 483s or other enforcement actions immediately.

Scope of Regulation

The product scope also differs. In the U.S., the FDA’s purview is very broad – it regulates foods, dietary supplements, drugs, biologics, devices, radiation-emitting products, tobacco, cosmetics, and animal drugs or feed (^[28]). Notably, FDA authority extends deeply into human foods and even pet food. By comparison, the EMA’s statutory remit is confined to medicines (human and veterinary). (Food safety in Europe is handled by separate EU agencies or national ministries.) The EMA does have a role in associating with medical devices: it supports conformity assessments for certain advanced therapies that incorporate devices or combination products, but it is not a primary device regulator (^[29]).

Besides product type, geography matters. FDA enforces laws on all U.S. territory, including U.S. clinics and trials; the EMA’s reach covers the 27 EU Member States plus EEA countries (Iceland, Norway, Liechtenstein) under the European Commission’s umbrella. Post-Brexit, the United Kingdom now has its own MHRA regulator (though MHRA cooperates with EMA-like networks). Switzerland similarly uses Swissmedic. Nevertheless, EMA rules (like pediatric legislation) can still indirectly influence activity in the UK if companies wish parallel filings there.

Finally, legal accountability differs. The FDA can impose penalties (seizures, injunctions, fines) under U.S. law if a company violates rules. The EMA itself cannot sue or prosecute firms; enforcement actions (product holds, fines for violations) happen via EU law or Member States’ laws, under the EU Regulation that created EMA. Thus, FDA’s decisions have immediate legal effect, while EMA’s opinions are implemented through EU-wide legislation. The U.S. Congress specifically reauthorizes the FDA’s user-fee laws (PDUFA, BsUFA) periodically, whereas the EMA budget is governed by EU financial regulations and multi-year programs (^[15]) (^[16]).

Before approval, both jurisdictions require rigorous clinical testing under Good Clinical Practice (GCP) to establish safety and efficacy. However, there are procedural differences in how trials are authorized and conducted in the US and EU.

Early-Stage Development and Trial Authorization

• United States (FDA and IND): In the U.S., developers must file an Investigational New Drug (IND) application with the FDA before beginning any human trials (^[30]). The IND includes preclinical animal data (Toxicology), the proposed manufacturing method, and the clinical trial protocol. The FDA then has 30 days to review the IND; if no clinical hold is issued, researchers may commence Phase 1 (safety) trials. During clinical development, sponsors can hold pre-IND, End-of-Phase-2, or pre-NDA/BLA meetings with the FDA to discuss plans and seek advice, which are generally accommodated by statute (e.g. the FDA is expected to grant at least one End-of-Phase-2 meeting to discuss trial designs) (^[31]). Investigators must also obtain Institutional Review Board (IRB) approval for each trial site. Federal registration and results-reporting requirements apply to certain "applicable clinical trials," as defined by FDAAA and implementing regulations; they do not apply to every trial that might be described as significant (^[32]).

• European Union (EMA & National CTAs): Historically, Europe did not have a single IND-like step. Each EU Member State has its own national authority that approves/declines clinical trial applications (CTAs). Today, a unified Clinical Trials Information System (CTIS) under the EU Clinical Trials Regulation 536/2014 (which became the sole legal framework for clinical trials in the EU as of January 2025, completing the transition from the earlier Directive) streamlines submission, but sponsors still obtain separate approvals from each national regulator and ethics committee in every country where trials will run (^[33]). In practice, a sponsor submits a single dossier via CTIS, but underlying national rules (production, import of IMPs) must be met. Like the U.S., EU trials begin at Phase 1 and progress (Phase 2, 3) similarly (^[34]). Because each state enforces its own standards, multi-country trial planning can be complex – although ICH GCP provides baseline global standards, implementation details (e.g. informed consent forms, monitoring practices) can vary. Under the Clinical Trials Regulation, sponsors submit EU/EEA clinical-trial applications through the Clinical Trials Information System (CTIS), which also supports public trial information and results. EudraCT and the EU Clinical Trials Register remain relevant mainly for legacy trials and certain third-country trials.

Despite these administrative differences, both systems have harmonized heavily on content: the main Structure of the Common Technical Document (eCTD) for submissions is the same, with region-specific Module 1 packages. In terms of conduct, both require adherence to GCP, risk-proportionate safety monitoring, and phased trials with increasing scale. Independent data monitoring committees may be useful or appropriate for some trials, but are not required for every trial.

Development Tools and Scientific Advice

To optimize development, both FDA and EMA offer formal advice mechanisms:

• FDA: Provides written meeting minutes or guidance after face-to-face Type A/B/C meetings at key points (pre-IND, end-of-Phase-2, pre-NDA, etc.) (^[35]) (^[36]). These are considered fairly "binding" in practice – FDA teams expect sponsors to follow agreed plans or object and communicate if plans change. The FDA also allows Special Protocol Assessment (SPA) in some cases, where the agency agrees that a trial design can be the basis of approval if completed as planned (commonly used for pivotal Phase 3 protocols).

• EMA: Offers Scientific Advice and Protocol Assistance (for orphan medicines) via a written Q&A, often with a subsequent meeting. This advice covers any development stage and is multidisciplinary (reflecting multiple member states’ views). It is not legally binding but is influential; companies typically respect the guidance or seek clarification. The EMA pioneered joint FDA–EMA parallel scientific advice (initiated in 2005) allowing sponsors to meet both agencies simultaneously with prepared questions, though this process has strict eligibility and limited slots (^[8]). Recently, the EMA also subsidizes academic advice via PRIME (for promising unmet-need therapies) to accelerate orphan and innovative drugs.

In both systems, failure to heed obtained advice is risky: regulators may issue refusals if a later submission deviates substantially from what was discussed without justification (^[37]). Sponsors often plan clinical programs embracing the stricter of the two sets of suggestions, or split trials to satisfy both. Some differences do arise: for example, as one comparison notes, the FDA may focus more on functional endpoints and quality-of-life measures in chronic diseases, whereas the EMA may demand safety data in vulnerable subgroups (^[38]). These nuances can force extra trials – for instance, as shown in a biosimilar case where one agency required a different comparative population than the other (^[39]). Overall, free-flowing scientific dialogue is a strength on both sides, even if not identically structured.

Once clinical data are gathered, the pathway to market diverges more significantly between FDA and EMA.

United States: IND → NDA/BLA → Approval

The U.S. process for new drugs is governed by the Food, Drug, and Cosmetic Act. After completing clinical trials under an IND, a sponsor submits either:

• NDA (New Drug Application) for small-molecule drugs, or
• BLA (Biologics License Application) for biologics (including biosimilars) (^[40]) (^[41]).

These submissions include the full Quality (CMC), nonclinical, and clinical sections (CTD Modules 2–5) and U.S.-specific administrative Module 1 (Form FDA 356h, patent certs, etc.) (^[42]). The FDA review team (from CDER or CBER as appropriate) then evaluates the application. By law, the FDA has 10 months to review a standard NDA/BLA (6 months if granted Priority Review for serious conditions) (^[43]). In practice, due to user-fee timelines and performance goals, many reviews target the ~10-month timeframe. During review, the FDA may inspect the manufacturing sites for compliance. The agency consults its advisory committees for ~20% of major deliberations. If the evidence shows substantial evidence of effectiveness and acceptable safety, the FDA approves the application and clears the drug for U.S. marketing.

Key points:

• The FDA directly authorizes the product: once approved, the drug can be sold nationwide immediately (^[44]).
• An approved NDA/BLA can grant all indications studied (unless label requests narrower use). There is no separate national or state-based approval beyond FDA’s action (unlike mutual recognition or national steps in EU).
• FDA assigns each NDA/BLA a standard or priority PDUFA user-fee review goal (e.g. target 10 or 6 months) (^[43]).
• Post-approval, changes to the application (manufacturing changes, new formulations) require supplements, which have their own FDA review.

European Union: Centralized and Alternative Procedures

The EU offers four regulatory routes for medicines, reflecting the diverse member states:

1. Centralized Procedure: This is mandatory for certain high-tech or high-impact medicines (e.g. biotech, orphan drugs, advanced therapies, treatments for HIV, cancer, diabetes, neurodegenerative disorders, viral diseases) (^[45]). The sponsoring company submits a single Centralized MAA to the EMA (via the EU website). The CHMP review (210-day timeline) yields an opinion. Once the EC grants approval, a single marketing authorization covers all EU/EEA states. This route ensures immediate multi-country access and is virtually the EMA analog of the FDA’s one-step NDA.

2. Decentralized Procedure (DCP): For non-centralized products, a company can apply in multiple EU countries simultaneously for a brand-new drug. One country acts as the Reference Member State preparing an assessment, which is then shared for other Concerned Member States to approve in their territories. If all agree, the drug receives separate but harmonized national licenses. DCP is now the most common route for products not requiring central review (^[46]).

3. Mutual Recognition Procedure (MRP): If a product is first approved in one EU country (via that country’s national system), the sponsor can use MRP to extend that approval to other member states, by mutual recognition of the dossier.

4. National Procedure: Each EU country (e.g. France, Germany) can approve essentially any drug that is not centrally mandated. National products are only marketed in the authorizing country unless later extended. (Post-Brexit, the UK’s MHRA took over all approvals in its territory, independent of EMA.)

Thus, unlike the FDA’s one-track NDA/BLA, the EMA operates a dual-layered and multi-path system (^[2]) (^[20]). The centralized route is most comparable to the FDA model (single application, one-license-for-all), while DCP/MRP achieve regional consensus licenses.

Timelines

• For centralized MAAs, the CHMP targets a 210-day active-review clock. However, this excludes pauses when the agency asks the company to answer questions (“clock stops”). In practice, the total time to EC decision after file submission is typically 12–15 months (^[43]).
• For national/DCP applications, each country has its own statutory timelines (often similar 210-day windows) plus mutual recognition steps that can add months. In practice, a simultaneous DCP in a handful of countries often spans a year or more to finish.

In summary, applicable PDUFA performance goals commonly call for FDA action on standard original NDA/BLA submissions within 10 months, while EU review can involve multiple steps and communications across countries that affect total elapsed time. These clocks measure different procedures and should not alone be treated as a like-for-like comparison of approval speed (^[47]; EMA centralised-authorisation guidance). Because a company can sometimes choose DCP instead of centralized (if eligible), it might even expedite EU entry by targeting a few key countries first. However, for blockbuster drug categories, centralized is mandatory in the EU by law.

Application Content and Format

Both agencies use the ICH eCTD format (Modules 2–5) to harmonize scientific content. Main differences lie in Module 1 (administrative) and nuances such as:

• FDA (Module 1): Requires Form 356h (application form), Information on Approval (patent, U.S. exclusivity), a comprehensive U.S. labeling content, and all documents in English. The FDA will also ask for patent certifications (Orange Book listing) and user-fee cover sheets.
• EMA (Module 1): Requires EU-specific forms (eAFs), company’s EU contact person, an EU SmPC template, package leaflet, and labelling in all EU official languages. Important is the Risk Management Plan (EU-RMP), which has an EU-standard format (different from the FDA’s REMS, though conceptually similar). Also, since 2007 the EMA requires a Paediatric Investigation Plan (PIP) for new drugs (with possible waivers or deferrals), reflecting EU pediatric law. The FDA’s pediatric requirements are principally handled under the Pediatric Research Equity Act (PREA), which authorizes FDA to require pediatric studies for certain drugs and biologics; Pediatric Study Plans (PSPs) and the Best Pharmaceuticals for Children Act address related planning and incentive mechanisms.

Regarding inspections, FDA assesses whether a pre-approval or pre-license inspection is necessary using a risk-based approach. A recent satisfactory inspection and relevant compliance history can support a waiver in appropriate cases; FDA may still inspect facilities when the application, site, or manufacturing changes warrant it. In the EU, GMP inspections are conducted by competent authorities in the EU medicines network rather than routinely by EMA staff for every MAA. In both systems, manufacturing facilities must comply with applicable GMP requirements.

When a drug addresses a serious condition or unmet medical need, both FDA and EMA offer accelerating pathways, but with different frameworks:

• FDA Expedited Programs: The FDA provides Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review – each with its own entry criteria and benefits (^[48]) (^[49]). For example, Fast Track allows more frequent FDA interaction and rolling review of sections; Breakthrough demands substantial improvement on endpoints and brings intensive FDA support; Accelerated Approval permits use of surrogate endpoints (with mandatory post-market confirmatory studies); and Priority Review places an eligible application in a PDUFA category with a 6-month FDA action goal rather than the 10-month goal that applies to many standard original applications (^[50]). These can be layered (e.g., a Fast Track drug can also get Priority Review and use Accelerated Approval). Under FDASIA (2012), the FDA expanded use of surrogate endpoints like progression-free survival in life-threatening diseases (^[51]). Significantly, the Food and Drug Omnibus Reform Act (FDORA) of December 2022 strengthened the Accelerated Approval program, including FDA authorities concerning confirmatory studies and withdrawal procedures. FDA's January 2025 document is draft, non-binding guidance. It explains that the statute permits FDA to require, as appropriate, that a confirmatory study be underway before approval or within a specified period after approval; it does not establish a universal actively-enrolling-patient requirement (^[52]).

• EMA Accelerated/Conditional Procedures: The EMA has a single Accelerated Assessment mechanism, cutting the 210-day review to 150 days for "innovative medicines of major interest" (^[53]). Entry into Accelerated Assessment requires application for eligibility. If the medicine is granted Accelerated Assessment, member states still have the same final EC timeline, but scientific evaluation is shorter. Separately, the EMA offers Conditional Marketing Authorization (CMA) for life-threatening diseases where clinical data are less complete. Under CMA, approval can be based on more limited Phase 2 data, provided the sponsor commits to completing studies post-approval. (This is akin to the FDA’s Accelerated Approval, although CMA also applies to new indications of existing drugs – by law EUA/CMA in US/EU have different scopes (^[54]).) The EMA also piloted adaptive pathways to gather conditional evidence from early phases, and the PRIME scheme (priority medicines) gives early EMA support for drugs addressing unmet needs (analogous to FDA Breakthrough Guidance).

Thus, while conceptually similar goals exist on both sides, the terminology and structure differ. For instance, the EMA does not have an exact analog for Fast Track by name – although companies can get frequent briefings via scientific advice. The table below highlights major expedited tools:

Accelerated Pathway	FDA (USA)	EMA (EU)
Priority/Fast Review Target	Priority Review: 6-month review (vs 10-mo standard) ([43]). Fast Track: rolling submission, more interactions. Breakthrough: intensive guidance.	Accelerated Assessment: 150-day review (vs 210-day standard) ([53]). Only one pathway for major innovations.
Premarket Support	Fast Track (early and frequent FDA meetings). Breakthrough (intensive guidance by FDA).	PRIME scheme (scientific support for unmet-need drugs, can lead to Accelerated Assessment) ([55]).
Conditional / Accelerated Approval	Accelerated Approval: allows approval on surrogate/endpoints for serious diseases (requires confirmatory Phase 4) ([51]).	Conditional MA: EMA can authorize based on preliminary data for unmet needs, requiring post-approval studies.
Orphan Drug Incentives	Orphan designation (<200k US patients): tax credits, waiver of FDA fees, 7-year market exclusivity.	Orphan designation (<5 in 10k EU population): fee reductions, 10-year market exclusivity, protocol assistance.

(Table: Summary of expedited programs in FDA vs EMA)

Overall, both agencies have flexibilities to speed access to critical drugs, but the FDA’s pluralistic suite (Fast Track, Breakthrough, etc.) often enables multiple overlapping benefits, whereas the EMA uses more singular mechanisms. In practice, US-sponsors frequently seek parallel designation in both (e.g. FDA Breakthrough + EMA PRIME) and engage in joint FDA–EMA advice to align strategies.

Although the basic legal standards (“safe and effective” in FDA law; “efficacious, safe and of good quality” in EU law) are aligned, interpretation and emphasis can differ in practice.

Efficacy Evidence

• FDA: By statute, the FDA requires substantial evidence of efficacy, traditionally defined as “two adequate and well-controlled trials” (^[10]). However, FDA may accept one convincing trial plus confirmatory evidence, especially for rare diseases or urgent conditions. Under Accelerated Approval, the FDA explicitly allows approval on validated surrogates (e.g., tumor shrinkage as a surrogate for survival in cancer) (^[51]). The FDA often enforces these standards strictly but has gradually shown willingness to accept innovative trial designs (e.g. single-arm trials for orphan oncology drugs, in recognition of urgency). The FDA has also begun accepting real-world evidence and historical controls in some cases.

• EMA: The EMA also demands rigorous proof. The nominal requirement is “comprehensive clinical data” (often two Phase 3 trials as well), but EU law gives the CHMP latitude to consider a wide evidence package and public health context. EMA scientists emphasize generalizability: are the patients, endpoints, and dosing reflective of European practice? They scrutinize consistency across multiple studies. The EMA does allow conditional approvals (for which a lower data bar applies, similar to FDA accelerated) (^[54]). EU guidelines have explicitly addressed small populations (rare diseases), single pivotal trials, and use of biomarkers. While the EMA uses surrogate endpoints less frequently than FDA, it does allow a single positive high-quality trial in exceptional cases (e.g. seriously ill cancer patients).

A comparative analysis of 2018–2022 orphan drug approvals found that for products approved only by FDA or only by EMA, the majority of exclusive approvals arose not from one agency lowering standards, but often because sponsors simply did not submit to the other agency or withdrew there (^[56]). Conversely, when both agencies reviewed a given orphan application, they usually arrived at the same decision (Figure 5-1 in Ref (^[56])). That suggests underlying evidentiary standards are broadly aligned and most apparent discrepancies stem from procedural or strategic factors.

The FDA has historically been more aggressive about anti-lag: for example, it was willing to approve Alzheimer’s drug aducanumab (Aduhelm) based on amyloid plaque clearance as a surrogate endpoint (^[57]), whereas the EMA demanded concrete clinical benefit and therefore rejected it (^[58]). (In January 2024, Biogen announced plans to discontinue Aduhelm’s development and commercialization; Medicare coverage had been limited to qualifying clinical studies.) The divergence continues with newer Alzheimer’s therapies: FDA granted lecanemab (Leqembi) accelerated approval in January 2023 and converted it to traditional approval on July 6, 2023. The European Commission granted EU marketing authorisation in April 2025 with a more restrictive indication limited to patients with no more than one copy of the ApoE4 gene. Similarly, donanemab (Kisunla) received traditional FDA approval in July 2024, while the EMA’s CHMP initially issued a negative opinion in March 2025 before reversing to a positive recommendation in July 2025, again with ApoE4-based restrictions. More generally, publications note that FDA’s accelerated program often relies on less robust data (surrogates, single-arm trials) as compared to EMA (^[6]). One analysis concludes, “the FDA tends to use faster and more flexible approval pathways and shows greater tolerance for uncertainty in benefit–risk assessments,” whereas “EMA shows a stronger focus on long-term safety and public health” (^[6]). Both systems require the applicant to submit evidence supporting a favorable benefit-risk assessment before marketing authorization. Differences in particular decisions should not be characterized as shifting the premarket burden to FDA to prove a drug unsafe.

However, the agencies often do reach the same scientific conclusion. For example, across novel drugs in the last decade, only a small minority had truly discordant decisions: some were approved in one region and refused in the other based on differing appreciation of data. Notable cases (see Chapter Case Studies) include Roxadustat (EMA-approved for anemia, FDA withheld approval for safety reasons) (^[59]), and Aducanumab (FDA-approved for Alzheimer’s on surrogate evidence, EMA rejected (^[58])). These counterexamples highlight institutional leanings. On the whole, parallel applications and early dialogue are encouraged in these high-stakes situations to minimize post-submission surprises.

Both agencies require labeling (package inserts) that detail indications, usage instructions, and safety information. The FDA publishes a Prescribing Information (PI) document in a U.S.-specific format; the EMA’s equivalent is the Summary of Product Characteristics (SmPC). EMA labeling must be prepared in all EU official languages and tends to reflect pan-European usage differences (e.g. dosing in mg/m² if Europe often uses it). The FDA’s label includes U.S.-centric data (e.g. gender/race pharmacology, and direct-to-patient Drug Facts sections for patient info) (^[3]) (^[60]).

Neither agency approves an indication beyond what was studied; however, the FDA’s labeling can sometimes include data from foreign trials extrapolated to U.S. populations if justified. The EMA will similarly include non-EU data but under the auspices of its committees. Pediatric information is explicitly required: U.S. sponsors must outline pediatric study results or plans to obtain pediatric exclusivity bonus; EU law requires PIPs or waivers as a condition of marketing authorization (^[61]).

Advisories on subpopulations (e.g. usage in pregnancy, geriatrics) are handled similarly via separate sections in each label. Notably, direct consumer advertising is only allowed in the U.S. (with FDA oversight) and is explicitly prohibited for prescription drugs in EU law.

Ensuring that drugs are made to high quality standards is integral. Both FDA and EMA enforce Good Manufacturing Practices (GMP), but the regulatory approaches have distinct emphases (^[11]).

• Guidance Style: The FDA’s GMP requirements are codified in 21 CFR Parts 210–211 and are very prescriptive. The regulations list many specific procedures (e.g. validations, batch record content). The FDA regularly issues extensive guidance documents interpreting the rules for drugmakers. Auditors focus on strict compliance; deviations typically lead to FDA regulatory letters or import alerts.

The EU’s GMP (EudraLex Vol. 4) is more principle-based (^[11]). Rather than enumerating every detail, it expects each manufacturer to implement a quality system and scientifically justify any deviations. EU rules require formal QRM (quality risk management under ICH Q9) in all GMP practices (^[12]) – until recently this was non-mandatory in the U.S. Only in updates to FDA guidance and legislation has risk management become more codified. EMA expects a “Qualified Person” (QP) to certify each batch release by attesting to quality standards, a role which has no direct FDA equivalent.

• Documentation and Records: Both agencies demand thorough records, but retention periods differ. The FDA mandates storage of records at least 1 year after product expiry (^[13]). By contrast, EU GMP requires batch documentation to be kept for at least one year after the batch expiry date or at least five years after certification by the Qualified Person, whichever is longer (^[14]). In practice, this means EU manufacturers often keep CMC records longer. The FDA also expects fresh raw data with original signatures and contemporaneous recording, whereas EMA similarly stresses documentation but as part of an integrated QMS (version controls, audit trails). A notable difference: the FDA’s ALCOA criteria for data integrity (Attributable, Legible, Contemporaneous, Original, Accurate) are explicitly enforced, whereas in the EU these principles are implied within GMP but perhaps less doctrinally referenced (since EMA typically relies on member states’ enforcement).

• Inspections: As noted, FDA inspectors (as federal officials) conduct routine and for-cause inspections domestically and at foreign sites making products for the U.S. The FDA can immediately take enforcement if violations are critical. EMA does not directly inspect on its own; it relies on inspections by EU national agencies (which are coordinated through inspections working parties). Because EU inspectors can only sanction manufacturing sites within their own country, the EMA uses a system of mutual recognition of inspection results. Under the Mutual Recognition Agreement (MRA) with the EU, FDA respectively may recognize inspections by EU agencies, though this has been limited to certain product types.

• Quality Work Culture: Commentators often say EU pharma labs emphasize systematic quality culture (QMS integration, training tied to job roles), whereas the FDA’s view has been more checklist-based. A lab manager’s guide highlights that the FDA historically was “prescriptive and rule-based,” whereas EMA is “directive and principle-based,” requiring quality risk management at all levels (^[11]) (^[12]). In training, FDA requires periodic GMP training per role; EMA requires training embedded in overall QMS with demonstration of competence (^[62]). While both seek high standards, a U.S. manufacturer must comply with one set of rules for its U.S. product, and a European manufacturer with another – often requiring parallel quality systems if the same plant supplies both markets.

In global practice, manufacturers selling in both regions typically maintain two overlapping GMP systems. For example, the EU requires a formal validation protocol for each process (Annex 15) and QP certification; FDA will inspect operations closely at approvals. Discrepancies can cause difficulties: EU Qualified Person certification and the FDA quality-control-unit requirement are different mechanisms. FDA cGMP requires a quality control unit with defined authority and responsibility to approve or reject drug-product components, specifications, procedures, and records. In short, quality expectations are universally high, but style and documentation differ, which has led to calls for regulatory convergence (e.g. ICH Q10 Quality System parallels). Nevertheless, supply chains must satisfy both cGMP (FDA) and EU GMP, often doubling the regulatory burden for global companies (^[63]) (^[64]).

After approval, both agencies continue to oversee safety and quality, but systems and emphasis vary:

• Reporting Systems: The FDA runs MedWatch, a spontaneous adverse event reporting system for U.S. healthcare providers and patients (^[65]). The EMA operates EudraVigilance, which collects reports from EU member states. Both regulators maintain public dashboards of reported events. However, because the EU has many national health systems, individual states also collect their own signals to report to EMA. The EU has more than 30 national pharmacovigilance centers, whereas the FDA’s adverse event analysis is centralized in one Agency.

• Safety Monitoring: The FDA continually evaluates post-market DME alerts, speedily issues safety communications, and can require updates to drug labels via official labeling supplements. The EMA, through PRAC and with member states, can recommend label changes or impose restricted use. In practice, both will suspend or withdraw a drug if new data show unacceptable risk (e.g. thalidomide was withdrawn in both decades ago, more recently certain cancer drugs have had unilateral actions like combination therapy withdrawals in Europe or black box warnings in the US).

• Batch Release: The FDA may require post-approval testing of drug batches (particularly biologics), but does not routinely test every batch before release. The EMA has a campaign for mutual recognition of batch testing with FDA (under MRA EU–US, some biologic tests by one agency could suffice for the other). For vaccines and biologics, both rely on manufacturing controls and periodic inspections more than end-product testing.

• Regulatory Actions: Differences arise in agility. FDA can issue an Import Alert to block products at borders (for example, banning a batch with GMP issues). EU safety reviews can involve EMA committees, the European Commission, and Member States, depending on the procedure. Nonetheless, large EU recalls and safety reviews are routine and often publicized by EMA announcements.

• Transparency: The EU has pushed greater transparency in post-approval: the EMA publishes European Public Assessment Reports (EPARs) for all centrally approved drugs, including extensive summaries of data. The FDA has historically been less transparent (released summary review documents with each approval, but less raw data share). This leads to differences in public scrutiny; for example, EMA’s EPAR for each central drug is analogous to the FDA’s Summary Review and Label, but published in layperson-friendly and technical versions.

Overall, both FDA and EMA claim comparable vigilance. Notably, one review of COVID-era accelerated approvals concluded that both systems delivered timely access without compromising safety; their adaptive programs were “flexible enough to grant emergency approvals while maintaining strict requirements” (^[66]). In normal times, continuous pharmacovigilance ensures feedback loops: e.g. EU Risk Management Plans (mandatory under EU law) evolve over years, similar to required post-marketing Phase 4 studies in the US. Patients in each region thus benefit from the cumulative oversight, even if processes differ.

Beyond approval, regulatory controls on labeling, promotion, and market conduct also differ:

• Labeling Content: FDA regulates prescription-drug labeling and promotion. Promotional materials generally must be submitted to FDA at initial dissemination, while pre-dissemination review applies in specified circumstances; FDA does not generally pre-approve every promotional item. The label (PI) is written in a structured U.S. format (including the Rx symbol, full prescribing information, and highlights for physicians). The EMA-required Summary of Product Characteristics has a different format (No Rx symbol, sections in different order, European units). Changes to labeling also differ: urgent safety revisions in the U.S. can be put into effect upon FDA agreement (and issues updated labeling by supplement). In the EU, the MAH usually submits label amendments to each country via a Type IA/IB variation (for minor changes) or Type II (for new warning) submitted to EMA or national agencies.

• Advertising Rules: The FDA strictly monitors prescription drug advertising to physicians and patients. Direct-to-consumer (DTC) TV advertising of prescription drugs is legal in the U.S. (the U.S. and New Zealand are the only large markets to allow this); these ads must summarize major risks and FDA markings. In the EU, DTC prescription drug advertising is illegal (^[67]). Pharmaceutical companies may promote to doctors via meetings or journals, but patient-directed ads (beyond general disease awareness without brand names) are forbidden. This cultural/regulatory gap is often cited as a major difference: U.S. patients are exposed to TV ads for new drugs, whereas Europeans are not. Social media content by pharma is regulated similarly (FDA provides guidance on online promotion; EMA oversees country-level enforcement).

• Off-Label Promotion: Both regulators forbid marketing beyond approved indications. FDA is vigilant about off-label promotion (via warning letters or prosecution). EU law also bans off-label marketing, though enforcement comes via member-state agencies, and the EMA will comment on it if flagged. Penalties can be severe in either system, but practices (and tolerances) vary.

• Counterfeit and Importation: FDA works to prevent entry of unauthorized drugs (e.g. importation from unapproved countries). The EMA has fewer enforcement arms and relies on member states' customs to block counterfeits. Unique device identification and serialization laws differ as well, largely because devices are regulated differently (the EU’s new Device Regulation vs FDA device rules).

In summary, while both agencies demand truthful, high-quality labeling, the FDA’s rules on advertising and labeling are more permissive (e.g. allowing U.S.-style DTC ads) and more centralized, whereas the EMA/EU framework is more restrictive (no DTC, multi-language labeling) and involves both EU law and national laws (e.g. national requirements for patient leaflets can vary by country). Companies must navigate a dual system of compliance when marketing globally.

The way the FDA and EMA are funded and staffed has important implications.

• FDA (U.S.): The FDA’s Center for Drug Evaluation and Research (CDER) is funded roughly two-thirds by user fees under PDUFA (Prescription Drug User Fee Act), with the remainder from Congressional appropriations. The current metric is about 69% of the drug budget covered by industry fees (^[15]). PDUFA is reauthorized periodically and establishes user-fee commitments and performance goals, including category-specific FDA action goals for applications; it does not create a universal binding deadline for a final approval decision (^[47]). This fee-driven model was explicitly intended to speed reviews but creates industry dependence: in fact, critics note that frequent reauthorization has led to expanded accelerated programs and lower evidentiary barriers (^[68]). FDA reports that it has more than 18,000 employees working in all 50 states and internationally (^[69]). Agency staffing and user-fee performance goals should not by themselves be used to infer the quality or duration of review in an individual application.

• EMA (EU): The EMA receives contributions from EU Member States (as “EU14”, recently ~20% of its budget), grants from the European Commission, and fees charged to industry (application fees, annual fees). By 2025, industry fees are expected to be over 90% of the EMA’s budget (^[16]). However, crucially, EMA fees are not linked to speed: the EU does not provide expedited funding for faster reviews. As a result, the EMA’s finances are somewhat stable and its deadlines are governed by the law (e.g. 210 days), not by fee agreements (^[16]). EMA relies on the EU medicines regulatory network, including national competent authorities and committee experts, for much of its scientific work. Its own reported headcount was 1,035 staff members as of December 2025, rather than several hundred (^[70]).

Table below summarizes these differences:

Aspect	FDA (US)	EMA (EU)
Funding	~69% user fees (PDUFA), rest federal budget ([15]).	~91% fees (application, yearly), plus EU grants/state aid ([16]).
Performance Goals	PDUFA performance goals to act on specified application categories; many original standard and priority NDA/BLA categories have 10- and 6-month goals, respectively.	The centralised procedure has a 210-day CHMP evaluation timetable, excluding clock stops; the Commission decision is a separate legal step.
Staffing	FDA reports more than 18,000 employees agency-wide; this figure is not limited to CDER reviewers.	EMA reported 1,035 core staff as of December 2025 and works through the wider EU medicines regulatory network.
Economic Pressure	High (industry fees create incentive to speed approvals) ([68]).	Lower (fees fund operations but not tied to speed ([16])).

(Table: Funding and Review Structure at FDA vs EMA)

The FDA’s user-fee model means pharmaceutical companies pay large sums to expedite reviews and can exert indirect influence (through fee negotiations) on FDA’s agenda (^[15]) (^[68]). For FY2025, the PDUFA application fee for a new drug requiring clinical data reached $4.31 million (rising to $4.68 million in FY2026), with total PDUFA base revenue exceeding $1.35 billion annually. The EMA underwent its own fee overhaul: Regulation (EU) 2024/568, effective January 1, 2025, shifted the EMA to a workload-based fee model, expanding marketing authorization application fees from 3 levels to 9, simplifying scientific advice fees, and eliminating fees for Type 1 variations and renewals while adding new pre-submission and re-examination fees. Since EMA fees still do not confer faster review, companies do not gain time by paying more. Observers conclude this gives the FDA more incentive to shorten reviews, whereas the EMA, under less time pressure, may devote more attention to long-term risk assessment (^[16]). The FY2026 President’s Budget proposed $6.8 billion for FDA, an overall decrease of $271.0 million, or 3.9%, from FY2025 enacted funding. The budget separately proposed an 11.4% decrease in discretionary budget authority, partly offset by increased user fees. The operational effect on review performance should not be assumed without current evidence. (^[71])

Capacities also differ by scale: because the U.S. population (~330M) dwarfs any single EU country, and because the pharmaceutical market is larger in dollar terms, the FDA generally handles more applications per year than EMA (583 vs 424 novel drugs 2013–2023 (^[72])). The FDA’s staff-to-product ratio is higher, enabling quicker turnovers. Moreover, the U.S. legal ecosystem allows class-action lawsuits and media scrutiny that can add incentives/disincentives, whereas the EMA’s work is less influenced by litigation (pharma lawsuits in Europe are rare compared to the US).

The above descriptions align with quantitative data on actual approvals:

• Approval Numbers (2013–2023): A 2025 analysis found 583 novel drug approvals by FDA vs 424 by EMA in that decade (^[72]). Not all these overlap – 347 were approved by both. The disparity reflects several factors: FDA’s single-track NDA/BLA system tends to capture all NME’s (including vaccines and gene therapies via CBER reports), whereas EMA’s count here only includes centralized-authorized drugs (national approvals were excluded). In practical terms, 185 drugs were FDA-only approvals, compared to only 42 EMA-only approvals (^[72]) (^[73]).

• Therapeutic Focus: Both agencies prioritized cancer, infectious diseases, immunology, and neurology, but FDA approved slightly more oncology drugs (with 89 of 583 for oncology) compared to EMA (59 of 424), hinting at faster US oncology approvals.

• Trends: The FDA’s approval count exceeded EMA’s every year through the study period. Both saw spikes in approvals after expedited pathways expanded. Independent studies (e.g. a NEJM review) have likewise noted that in most years the FDA completes reviews faster than EMA (^[5]). The reported 2024 and 2025 totals use different agency measures—FDA CDER novel-drug approvals and EMA recommendations containing a new active substance—so their raw difference should not be used as a general comparison of total FDA and EMA output. In 2025, the reported figures were 46 for CDER and 38 for EMA, respectively (^[74]; EMA human medicines in 2025). Notably, 2024 was the EMA’s strongest year since 2009, with 114 total medicine recommendations — the first time the agency exceeded 100. Of the FDA’s 2024 approvals, 22 (44%) were first-in-class and 26 had orphan drug designation, with 94% meeting PDUFA goal dates. The CancerNetwork review (2013) also emphasized that although critics sometimes claim Europe is faster, data consistently show the opposite: “the FDA typically approves drugs more quickly than the EMA” for both general and oncology drugs (^[75]).

• Review Times: As mentioned, multi-year trends confirm shorter median review durations at FDA. For 2011–2015, median FDA review was 306 days vs 383 days for EMA (^[5]). For jointly-approved drugs, FDA’s review was on average ~60 days faster (^[76]). This timing edge persists; for instance, a 2022 study found that for cancer drugs, the FDA granted approvals on average ~3-6 months ahead of EMA decisions across comparable products. However, whether the FDA can maintain this speed advantage amid significant staffing losses in 2025–2026 remains an open question.

• Accelerated Approvals (COVID as a case): During 2020–2022, for COVID-related vaccines and therapies, FDA granted 14 EUAs while EMA granted 12 conditional MAs (^[7]). Interestingly, both agencies delivered approvals on very rapid timetables (days to weeks) – far faster than normal pathways – demonstrating parallel commitment under crisis. The median approval time was ~24 days (EMA) vs 36 days (FDA) across all COVID medicines evaluated (^[7]), a close margin. The difference largely stemmed from regulatory structure: the EMA’s “conditional MA” could not cover new indications of existing drugs (whereas FDA’s EUA could) (^[9]), which affected how many applications fell into each category.

• Collaborative Outcomes: The FDA and EMA often accept each other’s data. For example, most drugs approved in both regions used the same pivotal trials. One analysis of dual-approved orphan drugs (2018–22) showed very similar endpoints and evidence. By contrast, among drugs approved by one side only, many were simply never submitted to the other (perhaps due to market size or expected difficulty). Where differences did occur, they are instructive: companies sometimes choose to submit first where the review is expected to be faster (often FDA) or where market potential is greatest. This has been called a form of “regulatory arbitrage” (^[77]).

In sum, data confirm the generalizations: the FDA’s system has yielded more and faster approvals, with greater use of flexibility, while the EMA has ensured high safety emphasis with slightly fewer approvals over the same period (^[72]) (^[6]). Both agencies review similar types of drugs (see next sections on pharmaceutical trends), but their benchmarks and timelines create measurable differences in the innovation pipeline.

To illustrate the regulatory divergences in practice, consider these representative cases:

COVID-19 Vaccines and Therapies

During the pandemic, both agencies launched extraordinary review processes (US: Emergency Use Authorization (EUA); EU: Conditional Marketing Authorization (CMA)). Ghadanian & Schafheutle (2023) compared all COVID-19 MAs in 2020–21 (^[7]). Both regulators granted a similar number of approvals (FDA: 14, EMA: 12). The median review time was extremely short – about 24 days (EMA CMA) vs 36 days (FDA EUA) for all COVID drugs, and ~23 vs 28 days for first-in-class vaccines/therapies (^[7]). These differences were minor given the context. Notably, FDA EUAs covered both new drugs and new indications for existing drugs, while EMA CMAs by regulation applied only to new products (^[9]). Overall, the study concluded both systems were effective in rapidly authorizing COVID medicines without compromising safety standards (^[66]).

This case exemplifies parallel accelerated pathways. Both agencies waived normal deadlines (FDA’s 30-day IND hold became immediate review; EMA’s review clock was effectively set at ~25 days for life-saving products). It also showed close coordination: the FDA and EMA held many joint teleconferences and published guidance together. In the end, major vaccines (Pfizer-BioNTech, Moderna, AstraZeneca) and therapeutics (monoclonal antibodies, antivirals) became available in both regions within weeks of each other.

Roxadustat (Evrenzo) – Divergent Safety Decisions

Roxadustat, an anemia drug, vividly illustrates differing risk tolerances. The EMA approved Roxadustat (Evrenzo) in 2021 for anemia in chronic kidney disease, noting manageable risks with a risk management plan (^[78]). The FDA, by contrast, rejected the application in the same year (^[59]). The FDA reviewers highlighted safety concerns (e.g. cardiovascular risks) and requested additional trials. Notably, after the FDA reanalysis insisted on changes, the sponsor applied post-hoc revisions to the Phase III dataset to try to show benefit, but FDA still withheld approval (^[59]). Ultimately, the company withdrew from pursuing U.S. market entry (^[79]).

This discrepancy stemmed from the EMA’s conclusion that the overall benefit–risk was positive (allowing approval with monitoring) versus FDA’s determination that the benefits did not clearly outweigh the risks. FDA and EMA saw the same data but interpreted the safety signals differently. This case underscores that, even for the same drug and indications, FDA can be more cautious (or require more confirmatory evidence) while EMA may be willing to accept uncertainty in exchange for earlier access.

Aducanumab (Aduhelm) – Accelerated vs Reject

A contrasting scenario is Biogen’s Alzheimer’s antibody aducanumab (marketed as Aduhelm). In 2021, the FDA granted Accelerated Approval for Aduhelm in Alzheimer’s disease (^[57]), accepting biomarker endpoints (beta-amyloid reduction despite mixed cognitive results) under provisions for diseases with high unmet need. This decision was controversial in the U.S., provoking debate over whether surrogate (plaque clearance) was an acceptable predictor of clinical benefit.

Meanwhile, the EMA refused the marketing application (^[80]). EMA experts pointed to serious concerns: trial studies were halted for futility, leaving only limited post hoc analyses, and the evidence that plaque reduction translated to cognitive improvement was deemed “insufficient.” They also noted a high incidence of amyloid-related imaging abnormalities (ARIA) and questioned safety. In sum, the EMA judged that “benefits did not outweigh the risks.” The FDA solution – accelerated approval contingent on a Phase 4 confirmatory trial (^[57]) – was not considered acceptable by the EMA.

These polar cases show the FDA’s historically higher threshold for accepting uncertainty in life-threatening contexts (Alzheimer’s has no treatments, making the FDA opt to give provisional access) (^[57]), compared to EMA’s more conservative stance. Both agencies framed their decisions as patient-centric, but used different risk–benefit analyses. Epilogue: In January 2024, Biogen announced plans to discontinue Aduhelm’s development and commercialization as part of a reprioritization of its Alzheimer’s disease portfolio. Medicare coverage had been limited to qualifying clinical studies under a 2022 coverage policy.

Lecanemab (Leqembi) and Donanemab (Kisunla) – The Next Generation of Alzheimer’s Divergences

The Aduhelm saga set the stage for a new round of FDA–EMA divergences over the next-generation anti-amyloid antibodies. Lecanemab (Leqembi), developed by Eisai and Biogen, received FDA accelerated approval in January 2023. On July 6, 2023, FDA converted that approval to traditional approval after reviewing the confirmatory CLARITY AD trial. The European Commission granted EU marketing authorisation in April 2025. The EU indication is limited to patients with no more than one copy of the ApoE4 gene, while FDA's indication is not limited by ApoE4 genotype; FDA labeling instead describes genotype-related ARIA risk and recommends testing to inform that risk.

Donanemab (Kisunla), developed by Eli Lilly, followed a similar but even more dramatic path. The FDA granted traditional (not accelerated) approval in July 2024 based on positive Phase 3 TRAILBLAZER-ALZ 2 results. The EMA’s CHMP issued a negative opinion in March 2025, citing ARIA in 36.8% of patients including three fatal outcomes. Eli Lilly requested re-examination in June 2025, and in July 2025 the CHMP reversed to a positive recommendation — but again restricted to ApoE4 noncarriers or heterozygotes only. These cases illustrate a consistent pattern: the FDA approves earlier with broader labeling, while the EMA takes longer but imposes risk-based restrictions to narrow the eligible population, reflecting its stronger emphasis on post-approval safety margins.

Cancer Drug Approvals – U.S. Speed vs European Consistency

In oncology, similar patterns emerge. For example, a review of six cancer indications approved by both agencies found FDA was faster on average by 3–9 months (^[75]). The CHMP often asked for additional data (e.g. confirmatory trials before approval) that the FDA waived if a surrogate endpoint was strong enough. One study quantified this: across multiple cancer drugs, the FDA’s review clock was significantly shorter than EMA’s. In one famous case, a new targeted therapy for leukemia reached the market in the U.S. in late 2017, but the EMA only approved it a year later after further trials.

From the industry perspective, these differences mean launch strategies diverge. U.S.-based companies often file first at FDA to get the earliest possible market entry, then submit to EMA. Delays in Europe (if any) can affect revenue. Conversely, EU companies might seek simultaneous filings to avoid a “drug lag.” Some have even lobbied for mutual recognition of approvals to shorten global lag. Notably, the 2013 review observed that FDA’s faster approvals “provide reassurance” on its performance, impacting debates like PDUFA reauthorization (^[81]).

Despite differences, FDA and EMA actively collaborate to harmonize standards and avoid duplication:

• Information Sharing: Since 2003, they have an confidentiality agreement allowing shared access to nonpublic data (e.g. safety reports, inspection results) (^[82]) (^[83]). They hold regular technical “cluster” meetings on topics from generics to oncology.

• Parallel Advice: As noted, sponsors can request Parallel Scientific Advice, where FDA and EMA experts give coordinated feedback on development plans. Though this still occurs infrequently, it aims to iron out divergences early.

• Regulatory Reliance: The EU–US Mutual Recognition Agreement for human-medicine GMP inspections took effect in 2017; all EU Member States had been confirmed as capable of carrying out GMP inspections for the agreement by 2019. The October 2025 update expanded reliance on FDA inspections conducted in third countries and described staged work on extending the agreement to veterinary medicines. It did not newly confirm the named Member States’ human-medicine inspection capability. The agreement can reduce duplicative inspections when its conditions and scope are met.

• International Initiatives: Both agencies participate in ICH (International Council on Harmonisation) to align standards on technical requirements. A landmark development was ICH E6(R3) — the updated Good Clinical Practice guideline — which the EMA made effective in July 2025 and the FDA posted in final form in September 2025 (though a formal U.S. compliance date has not yet been set). ICH E6(R3) modernizes GCP to accommodate decentralized clinical trials, pragmatic trial designs, and real-world data collection — areas where FDA and EMA had previously taken divergent approaches. Other recent ICH milestones include ICH M12 (drug interaction studies), finalized in 2024 and adopted by both agencies, and the establishment of an ICH Cell and Gene Therapy Discussion Group to develop harmonized frameworks for advanced therapy medicinal products. Both agencies also joined OECD work-sharing and the International Coalition of Medicines Regulatory Authorities (ICMRA) for global emergencies. Efforts like the Common Technical Document (CTD) itself are fruits of harmonization – enabling largely overlapping dossier content.

• Joint AI/ML Initiatives: In January 2026, the FDA and EMA jointly published 10 guiding principles for the use of artificial intelligence and machine learning in drug development, building on a bilateral meeting held in April 2024 and the EMA's September 2024 AI reflection paper. This joint guidance covers AI applications across the drug lifecycle — from target discovery and clinical trial design to manufacturing quality control. The EMA is also consulting on a new GMP Annex 22 specifically addressing AI use in pharmaceutical manufacturing, an area where no FDA-specific guidance yet exists.

However, full convergence is elusive. Legislative differences (e.g. EU pediatric rule vs US approach, or vaccine liability laws) limit legal alignment. Moreover, each agency answers to different government bodies and stakeholders (FDA to Congress and U.S. public, EMA to EU Parliament and national ministries). Analysts note a kind of “regulatory parallelism” where both agencies have analogues for most processes but rarely identical rules. The COVID-19 response showed how joint training and crisis Intel-sharing can force convergence, but under normal conditions, FDA and EMA mostly work side-by-side.

Understanding how regulatory differences translate into public health impact requires data on approvals, safety actions, and access. Key findings include:

• Approval Rates by Therapeutic Area: Both agencies prioritize similar disease areas (oncology, autoimmunity, neurodegeneration, etc.) (^[17]). The FDA has approved more novel oncology agents (reflecting U.S. biotech activity) while EMA’s approvals include more anti-infectives and vaccines (perhaps due to European R&D patterns).

• Use of Surrogate Endpoints: Studies show the FDA is statistically more likely to accept surrogate endpoints. A 2020 BMJ cohort found that 31% of FDA’s accelerated approvals were based on surrogate outcomes, vs only ~7% of EMA’s conditional approvals (^[6]) (reflecting the line “surrogate endpoints…the FDA uses more frequently…as opposed to EMA’s focus on long-term outcomes” (^[6])).

• Regulatory Reviews Over Time: Trends indicate FDA has slightly increased its volume of approvals post-2010 (especially with more orphan designations and breakthrough approvals) whereas EMA’s volume has grown more modestly. A ratio based on FDA CDER novel-drug approvals and EMA recommended medicines with new active substances is not a harmonized cross-agency metric, because the agencies' reports use different scopes and definitions. For 2025, FDA CDER reported 46 novel drugs and EMA reported 38 recommended medicines containing a new active substance (^[74]; EMA human medicines in 2025). The EMA has also seen a surge in biosimilar recommendations (41 in 2025 alone), reflecting Europe’s stronger biosimilar market compared to the U.S.

• Parallel Approvals: Approximately 70–80% of new molecular entities are eventually approved by both agencies (though not always concurrently) (^[72]). When a drug gets one but not the other, it’s often because the sponsor never filed, not necessarily because of rejection. Table 6 in Ecker et al. (2025) highlights contested cases, showing the breadth of reasons (safety differences, insufficient data, different indications) (^[59]) (^[58]).

These comparisons should be interpreted within their study periods, product definitions, and submission populations. Differences in approval timing or use of specific pathways do not establish a universal agency-level preference for speed, uncertainty, or safety, and raw agency totals are not directly comparable when their reporting scopes differ. Both regulators make product-specific benefit–risk decisions and maintain post-authorisation safety systems.

The implications of FDA–EMA differences are manifold. For pharmaceutical companies, double compliance is costly: they must build registries and trial sites for both systems, prepare dual submissions, and may need separate phases of product release. Economically, the more flexible U.S. market can be more attractive for first launch for many new drugs, boosting U.S. access relative to Europe. Conversely, European pricing and reimbursement schemes (not covered by these agencies) ultimately influence where drugs actually reach patients.

For patients and physicians, the trade-offs play out as speed versus certainty. U.S. patients often gain earlier access to new therapies (especially in oncology and rare diseases) (^[5]) (^[75]), but sometimes at the cost of later post-market surprises (e.g. FDA Withdrawals like darvon, mabs with cardio risks). European patients might wait months longer but do so with slightly more safety data in hand and without direct-to-patient drug marketing influencing demand.

Looking ahead, harmonization efforts will continue alongside legislative and operational changes. The EU pharmaceutical package reached a provisional political agreement in December 2025 after negotiations on Commission proposals issued in April 2023. At the latest update, formal Council adoption remained expected after legal and linguistic checks, and Parliament's final plenary vote was not yet scheduled, with an indicative autumn 2026 date. Until both co-legislators formally adopt the package and it is published, its final legal text and implementation timetable should not be presented as settled.

Both regulators face new challenges in regulating AI-developed therapeutics, gene-editing therapies, and digital health products — areas where their January 2026 joint AI/ML principles represent an early attempt at coordinated approaches. FDA’s Project Orbis provides a framework for concurrent oncology-product review with FDA’s listed international partners; EMA is not listed as a Project Orbis partner (^[84]). The expanded MRA for GMP inspections (October 2025) reduces redundancy. FDA’s PDUFA VIII reauthorization process is already underway for fiscal years 2028–2032; PDUFA VII authority expires in September 2027 (^[85]). The EMA has launched initiatives to streamline reviews and address orphan approval backlogs, while the incoming EU pharmaceutical legislation will introduce stricter benefit–risk frameworks and new incentive structures. Their roles will also be shaped by external policy: U.S. legislative proposals on drug pricing, EU debates on speed vs safety, and growing patient advocacy in both regions.

Ultimately, the FDA and EMA operate under different legal structures and procedures while serving public-health missions. Their distinct routes to authorisation, review-goal frameworks, and post-authorisation systems can affect development planning, but agency-wide characterizations of one regulator as inherently faster, more industry-aligned, or more precautionary are interpretations rather than settled facts. Product-specific comparisons should identify comparable submission populations, procedures, and review clocks.

The FDA and EMA each wield profound influence over the safety and availability of medicines in their regions. This report has dissected their regulatory frameworks, revealing that while built on the same scientific foundations, the U.S. and European systems diverge in structure, process, and philosophy. The FDA makes nationwide U.S. marketing decisions, while EMA scientific opinions in the centralised procedure lead to European Commission decisions valid across the EU/EEA. Each system has expedited and conditional pathways, and cross-agency review-time comparisons must account for differing procedures, submission populations, and clock-stop rules.

These differences manifest at every stage: from clinical trial authorizations (the U.S. IND process versus EU applications through CTIS with Member State decisions) to dossier review (NDA versus CHMP opinion), to post-market policing (MedWatch versus EudraVigilance). Quantitative data back this up: historically the FDA has approved more novel drugs and done so more quickly than the EMA (^[72]) (^[5]). Yet, both agencies strive for the same target – ensuring only safe and effective therapies reach patients. Indeed, in most cases they achieve concordant outcomes.

For industry and researchers, understanding the nuances – the “FDA vs EMA gap” – is critical for successful global drug development. Regulatory strategy must account for varying evidence expectations (especially around single trials and patient-reported outcomes) and the need for additional studies if dual approvals are sought. This dual-counsel system also raises costs and complexity. For patients, these differences mean a drug might reach one market months before the other, or might be handled differently upon facing new risks.

Looking to the future, continued convergence is unlikely to erase all differences. The agencies answer to different legal societies and healthcare systems. However, ongoing collaboration (joint guidelines, shared reviews, common crisis response) promises to narrow gaps. International patients are now linked by global health concerns, and regulators increasingly recognize the value of harmonization. Meanwhile, emergent therapies – from gene editing to digital cures – may prompt new regulatory thinking on both sides. In the final analysis, the FDA vs. EMA dynamic illustrates how local jurisdiction shapes even universal scientific endeavors. Both agencies will continue to learn from each other, refining “best practices” in drug regulation, but they will do so in ways that reflect the unique priorities of American and European societies.

References:

• Ecker, A. et al. (2025). Comparison of drug approvals of the FDA and EMA between 2013 and 2023. Naunyn-Schmiedeberg’s Arch. Pharmacol. (open access) (^[72]) (^[6]).
• Ghadanian, M., & Schafheutle, E. (2023). Comparison between EMA and FDA in granting accelerated authorizations for COVID-19 medicines. Ther. Innov. Regul. Sci. (open access) (^[7]) (^[9]).
• Salib, V. (2023). Regulating and Authorizing Medicines: FDA vs EMA. TechTarget (^[86]) (^[87]).
• Howie, L.J. et al. (2013). Comparison of FDA and EMA drug approval. Cancer Network (^[75]).
• Mabion (2019). Differences Between EMA and FDA. Mabion Science Hub (^[88]) (^[28]).
• Bradley, C. (2024). FDA vs EMA: GMP differences. Lab Manager (^[11]) (^[14]).
• Van Norman, G. (2016). Drugs and Devices: EU vs US Approval. JACC Basic Transl. Sci. (^[18]) (^[2]).
• NCBI (2024). Regulatory Processes for Rare Disease Drugs in US and EU. National Academies Press (^[89]) (^[10]).
• FDA.gov / EMA.europa.eu official sites on agency mission and regulations (^[90]) (^[91]).
• FDA (2025). Novel Drug Approvals for 2024. U.S. Food and Drug Administration.
• EMA (2025). Human medicines highlights 2024. European Medicines Agency.
• FDA (2025). Prescription Drug User Fee Rates for Fiscal Year 2026. Federal Register.
• EMA (2025). Regulation (EU) 2024/568 on EMA fees. Official Journal of the European Union.
• FDA & EMA (2026). Joint guiding principles on the use of AI/ML in drug development. January 2026.
• ICH (2025). ICH E6(R3) Good Clinical Practice. International Council for Harmonisation.
• (Other sources as cited throughout text.)